KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-MSH and retains much of α-MSH's anti-inflammatory activity without pigmentary effects. Preclinical work in colitis and skin inflammation models.
KPV is the C-terminal tripeptide (lysine-proline-valine) of α-melanocyte-stimulating hormone (α-MSH). It retains much of the parent hormone’s anti-inflammatory activity while shedding its pigmentary effects, making it a focused research tool for inflammation.
Preclinical studies report that KPV reduces pro-inflammatory signaling — in part by interfering with the NF-κB pathway — in models of colitis, skin inflammation, and oral inflammation. It is a research compound and is not FDA-approved.
NF-κB pathway inhibition; reduction of pro-inflammatory cytokines.
Behind every vial of KPV is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how KPV, specifically, is brought into being.
On paper, KPV is C16H30N4O4 — about 342.4 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling KPV means roughly 3 coupling cycles on the synthesizer — one protected residue added at a time, which is also 3 chances for an incomplete coupling to seed a deletion impurity. It is a short sequence, which makes the build comparatively tractable — but short does not mean trivial, and purity is still won or lost downstream.
The crude mixture — KPV plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of KPV proves itself: identity confirmed by mass spectrometry against its ~342.4 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of KPV — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing KPV to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning KPV, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
KPV is the anti-inflammatory C-terminal tripeptide of α-MSH, studied in preclinical models of colitis and skin inflammation.
KPV is the final three residues of α-MSH and keeps much of its anti-inflammatory activity without the pigmentation effect.
Inflammatory bowel disease, atopic dermatitis, and oral inflammation, primarily in preclinical models.
No — it is a research compound. This page is a research and educational reference.
Dosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.